Free tool
FAERS Monitor: Dexmedetomidine Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206628 or its brand name (Dexmedetomidine Hydrochloride, Dexmedetomidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,243
Serious
5,001
95% of reports
Hospitalization
2,475
Death reported
568
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use608
- drug ineffective450
- bradycardia418
- hypotension313
- cardiac arrest263
- drug interaction261
- agitation202
- product use in unapproved indication174
- respiratory failure167
- delirium153
- pyrexia146
- tachycardia146
- toxicity to various agents143
- acute kidney injury127
- diabetes insipidus119
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 1 |
| 2008 | 8 |
| 2009 | 18 |
| 2010 | 24 |
| 2011 | 29 |
| 2012 | 30 |
| 2013 | 90 |
| 2014 | 103 |
| 2015 | 80 |
| 2016 | 220 |
| 2017 | 244 |
| 2018 | 211 |
| 2019 | 348 |
| 2020 | 512 |
| 2021 | 571 |
| 2022 | 552 |
| 2023 | 613 |
| 2024 | 659 |
| 2025 | 582 |
| 2026 | 342 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,916 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diabetes insipidusSignal | 119 | 208.5 | 173.8 | 23,170 |
| bradycardiaSignal | 418 | 31.9 | 29.1 | 12,401 |
| deliriumSignal | 153 | 17.8 | 15.2 | 2,397 |
| cardiac arrestSignal | 263 | 12.8 | 11.4 | 2,856 |
| agitationSignal | 202 | 11.1 | 9.7 | 1,840 |
| respiratory failureSignal | 167 | 9.2 | 7.9 | 1,215 |
| drug interactionSignal | 261 | 6.6 | 5.9 | 1,244 |
| tachycardiaSignal | 146 | 6.6 | 5.6 | 690 |
| hypotensionSignal | 313 | 6.3 | 5.6 | 1,392 |
| toxicity to various agentsSignal | 143 | 3.4 | 2.9 | 242 |
| acute kidney injurySignal | 127 | 3.3 | 2.8 | 206 |
| product use in unapproved indicationSignal | 174 | 2.8 | 2.4 | 204 |
| off label useSignal | 608 | 2.8 | 2.6 | 724 |
| pyrexia | 146 | 1.7 | 1.4 | 41 |
| drug ineffective | 450 | 1.4 | 1.3 | 48 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.